Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

This phase II study is the first prospective evaluation of bortezomib-dexamethasone as second-line therapy for relapsed/refractory multiple myeloma. A total of 163 patients were enrolled to receive four cycles of bortezomib-dexamethasone. Patients were investigator-assessed for response at cycle 5 D...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dimopoulos, Meletios A., Beksac, Meral, Benboubker, Lotfi, Roddie, Huw, Allietta, Nathalie, Broer, Esther, Couturier, Catherine, Mazier, Marie-Andrée, Angermund, Ralf, Facon, Thierry
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2013
Assuntos:
Original Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3729908/
https://ncbi.nlm.nih.gov/pubmed/23716559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.084376
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados